- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06524544
Eine Studie zum Vergleich der Kombination von Pembrolizumab und Sacituzumab-Govitecan mit Sacituzumab-Govitecan allein bei der Behandlung von fortgeschrittenem Urothelkrebs
Eine randomisierte Phase-III-Studie mit Pembrolizumab in Kombination mit Sacituzumab Govitecan im Vergleich zu Sacituzumab Govitecan allein bei Anti-PD(L)1-resistentem fortgeschrittenem Urothelkrebs
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Arzneimittel: Carboplatin
- Arzneimittel: Paclitaxel
- Arzneimittel: Cisplatin
- Arzneimittel: Docetaxel
- Verfahren: Biospecimen Collection
- Verfahren: Computed Tomography
- Verfahren: Magnetic Resonance Imaging
- Sonstiges: Questionnaire Administration
- Biologisch: Pembrolizumab
- Arzneimittel: Gemcitabine
- Biologisch: Sacituzumab Govitecan
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) between the therapy of physician choice (TPC) arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
SECONDARY OBJECTIVES:
I. To compare the progression free survival (PFS) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
II. To evaluate overall response rate (ORR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
III. To evaluate clinical benefit rate (complete response [CR]/partial response [PR] /stable disease [SD]) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To evaluate duration of response (DoR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To evaluate toxicity of the Sacituzumab govitecan-hziy + pembrolizumab arm using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
EXPLORATORY HEALTH RELATED QUALITY OF LIFE (HRQOL) OBJECTIVES:
I. To compare HRQOL, as assessed by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at 6 months.
II. To compare HRQOL change from baseline, as assessed by the FBISI-18 summary score, for patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at baseline, 3, 6, and 12 months.
III. To compare the change in patient-reported fatigue from baseline and across 3, 6, and 12 months as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) summary score; change from baseline will be compared between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To compare quality-adjusted survival (overall survival x health utility score assessed by the European Quality of Life Five Dimension Five Level [EQ-5D-5L]) between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To compare time to HRQOL deterioration in global HRQOL, as measured by the FBISI-18 disease-related physical symptom subscale (FBISI-18 disease-related symptoms (DRS) in the physical emotional domains [DRS-P]), between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive TPC with carboplatin or cisplatin intravenously (IV) on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.
ARM B: Patients receive sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles or for 2 years of pembrolizumab in the absence of disease progression or unacceptable toxicity. Cycles of sacituzumab govitecan-hziy repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.
After completion of study treatment, patients are followed up at 30 days then once a year for 5 years from the date of randomization.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85004
- Rekrutierung
- Cancer Center at Saint Joseph's
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
-
California
-
Irvine, California, Vereinigte Staaten, 92612
- Rekrutierung
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-Mail: ucstudy@uci.edu
-
Hauptermittler:
- Nataliya Mar
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-Mail: ucstudy@uci.edu
-
Hauptermittler:
- Nataliya Mar
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- Rekrutierung
- UF Health Cancer Institute - Gainesville
-
Hauptermittler:
- Daniel V. Araujo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hauptermittler:
- Jacqueline T. Brown
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Rekrutierung
- Emory University Hospital Midtown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Hauptermittler:
- Jacqueline T. Brown
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Rekrutierung
- Emory Saint Joseph's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Hauptermittler:
- Jacqueline T. Brown
-
-
Idaho
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Rekrutierung
- Kootenai Health - Coeur d'Alene
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Rekrutierung
- Kootenai Clinic Cancer Services - Post Falls
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Rekrutierung
- Kootenai Clinic Cancer Services - Sandpoint
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hauptermittler:
- Karine Tawagi
-
Danville, Illinois, Vereinigte Staaten, 61832
- Rekrutierung
- Carle at The Riverfront
-
Hauptermittler:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Cancer Care Specialists of Illinois - Decatur
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Decatur Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Priyank P. Patel
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Crossroads Cancer Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Rekrutierung
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Priyank P. Patel
-
Normal, Illinois, Vereinigte Staaten, 61761
- Rekrutierung
- Carle BroMenn Medical Center
-
Hauptermittler:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
Normal, Illinois, Vereinigte Staaten, 61761
- Rekrutierung
- Carle Cancer Institute Normal
-
Hauptermittler:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Cancer Care Center of O'Fallon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- HSHS Saint Elizabeth's Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Shiloh, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Memorial Hospital East
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-747-9912
- E-Mail: dschwab@wustl.edu
-
Hauptermittler:
- Melissa A. Reimers
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Springfield Clinic
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Rekrutierung
- Springfield Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-528-7541
- E-Mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Priyank P. Patel
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- Rekrutierung
- Mary Greeley Medical Center
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Ames, Iowa, Vereinigte Staaten, 50010
- Rekrutierung
- McFarland Clinic - Ames
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-239-4734
- E-Mail: ksoder@mcfarlandclinic.com
-
Boone, Iowa, Vereinigte Staaten, 50036
- Suspendiert
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 319-365-4673
-
Hauptermittler:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Rekrutierung
- Oncology Associates at Mercy Medical Center
-
Hauptermittler:
- Deborah W. Wilbur
-
Kontakt:
- Site Public Contact
- Telefonnummer: 319-363-2690
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- Rekrutierung
- McFarland Clinic - Trinity Cancer Center
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Jefferson, Iowa, Vereinigte Staaten, 50129
- Suspendiert
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Vereinigte Staaten, 50158
- Rekrutierung
- McFarland Clinic - Marshalltown
-
Hauptermittler:
- Joseph J. Merchant
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
-
Kansas
-
Hays, Kansas, Vereinigte Staaten, 67601
- Rekrutierung
- HaysMed
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-623-5774
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Rekrutierung
- University of Kansas Cancer Center
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, Vereinigte Staaten, 66044
- Rekrutierung
- Lawrence Memorial Hospital
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-505-2800
- E-Mail: Stephanie.Norris@LMH.ORG
-
Olathe, Kansas, Vereinigte Staaten, 66061
- Rekrutierung
- The University of Kansas Cancer Center - Olathe
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-1569
- E-Mail: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Vereinigte Staaten, 66210
- Rekrutierung
- University of Kansas Cancer Center-Overland Park
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Salina, Kansas, Vereinigte Staaten, 67401
- Rekrutierung
- Salina Regional Health Center
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-452-7038
- E-Mail: mleepers@srhc.com
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Rekrutierung
- University of Kansas Health System Saint Francis Campus
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-295-8000
-
Westwood, Kansas, Vereinigte Staaten, 66205
- Rekrutierung
- University of Kansas Hospital-Westwood Cancer Center
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- The James Graham Brown Cancer Center at University of Louisville
-
Hauptermittler:
- Rohit Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-562-3429
-
Louisville, Kentucky, Vereinigte Staaten, 40245
- Rekrutierung
- UofL Health Medical Center Northeast
-
Hauptermittler:
- Rohit Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-852-2755
- E-Mail: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70809
- Rekrutierung
- Louisiana Hematology Oncology Associates LLC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-215-1353
- E-Mail: clinicalresearch@marybird.com
-
Hauptermittler:
- Scott E. Delacroix
-
Metairie, Louisiana, Vereinigte Staaten, 70002
- Rekrutierung
- Mary Bird Perkins Cancer Center - Metairie
-
Hauptermittler:
- Scott E. Delacroix
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-584-6990
-
-
Massachusetts
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Rekrutierung
- UMass Memorial Medical Center - University Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-Mail: cancer.research@umassmed.edu
-
Hauptermittler:
- Kriti Mittal
-
-
Michigan
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Houssam Y. Hariri
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Houssam Y. Hariri
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Houssam Y. Hariri
-
Lansing, Michigan, Vereinigte Staaten, 48912
- Rekrutierung
- University of Michigan Health - Sparrow Lansing
-
Kontakt:
- Site Public Contact
- Telefonnummer: 517-364-3712
- E-Mail: harsha.trivedi@umhsparrow.org
-
Hauptermittler:
- Houssam Y. Hariri
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Houssam Y. Hariri
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Houssam Y. Hariri
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Houssam Y. Hariri
-
-
Minnesota
-
Brainerd, Minnesota, Vereinigte Staaten, 56401
- Rekrutierung
- Essentia Health Saint Joseph's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Rekrutierung
- Essentia Health - Deer River Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Rekrutierung
- Essentia Health Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Fairview Southdale Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Rekrutierung
- Essentia Health Hibbing Clinic
-
Hauptermittler:
- Bret E. Friday
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
-
Marshall, Minnesota, Vereinigte Staaten, 56258
- Rekrutierung
- Avera Cancer Institute at Marshall
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-Mail: OncRegulatory@avera.org
-
Hauptermittler:
- Ryan A. Vaca
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Rekrutierung
- Abbott-Northwestern Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- Rekrutierung
- United Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Rekrutierung
- Essentia Health Sandstone
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Rekrutierung
- Essentia Health Virginia Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Rekrutierung
- Saint Francis Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-Mail: sfmc@sfmc.net
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Rekrutierung
- Siteman Cancer Center at Saint Peters Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Melissa A. Reimers
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Siteman Cancer Center at West County Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Melissa A. Reimers
-
Farmington, Missouri, Vereinigte Staaten, 63640
- Rekrutierung
- Parkland Health Center - Farmington
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Kansas City, Missouri, Vereinigte Staaten, 64154
- Rekrutierung
- University of Kansas Cancer Center - North
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Rekrutierung
- University Health Truman Medical Center
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-404-4375
-
Kansas City, Missouri, Vereinigte Staaten, 64116
- Rekrutierung
- University of Kansas Cancer Center - Briarcliff
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
-
Lee's Summit, Missouri, Vereinigte Staaten, 64064
- Rekrutierung
- University of Kansas Cancer Center - Lee's Summit
-
Hauptermittler:
- Saqib Abbasi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Rekrutierung
- Sainte Genevieve County Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Melissa A. Reimers
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Rekrutierung
- Siteman Cancer Center-South County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Melissa A. Reimers
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Rekrutierung
- Siteman Cancer Center at Christian Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Melissa A. Reimers
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Rekrutierung
- Missouri Baptist Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Rekrutierung
- Missouri Baptist Sullivan Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Rekrutierung
- Community Hospital of Anaconda
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Billings, Montana, Vereinigte Staaten, 59101
- Rekrutierung
- Billings Clinic Cancer Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-996-2663
- E-Mail: research@billingsclinic.org
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Rekrutierung
- Bozeman Health Deaconess Hospital
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Rekrutierung
- Benefis Sletten Cancer Institute
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Rekrutierung
- Logan Health Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Missoula, Montana, Vereinigte Staaten, 59804
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@dartmouth.edu
-
Hauptermittler:
- Jacob B. Reibel
-
-
New Jersey
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Rekrutierung
- Cooperman Barnabas Medical Center
-
Hauptermittler:
- Biren Saraiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
Long Branch, New Jersey, Vereinigte Staaten, 07740
- Rekrutierung
- Monmouth Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-Mail: mary.danish@rwjbh.org
-
Hauptermittler:
- Biren Saraiya
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Hauptermittler:
- Biren Saraiya
-
Newark, New Jersey, Vereinigte Staaten, 07101
- Rekrutierung
- Rutgers New Jersey Medical School
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Hauptermittler:
- Biren Saraiya
-
Somerville, New Jersey, Vereinigte Staaten, 08876
- Rekrutierung
- Robert Wood Johnson University Hospital Somerset
-
Hauptermittler:
- Biren Saraiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 908-685-2481
- E-Mail: Siby.Varughese@rwjbh.org
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- Biren Saraiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-Mail: Lennette.Gonzales@rwjbh.org
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Rekrutierung
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Ellis G. Levine
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Rekrutierung
- Stony Brook University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-862-2215
-
Hauptermittler:
- Judy Huang
-
Williamsville, New York, Vereinigte Staaten, 14221
- Rekrutierung
- Roswell Park Amherst Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Ellis G. Levine
-
-
North Carolina
-
Hendersonville, North Carolina, Vereinigte Staaten, 28791
- Rekrutierung
- Margaret R Pardee Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-696-4716
- E-Mail: pardeecancerresearch@unchealth.unc.edu
-
Hauptermittler:
- John K. Hill
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58103
- Rekrutierung
- Essentia Health Cancer Center-South University Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- Ohio State University Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-293-5066
- E-Mail: Jamesline@osumc.edu
-
Hauptermittler:
- Yuanquan Yang
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Adanma Anji Ayanambakkam Attanathi
-
-
Pennsylvania
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Rekrutierung
- Geisinger Medical Center
-
Hauptermittler:
- Sorab Gupta
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-Mail: cancerresearch@geisinger.edu
-
Dickson City, Pennsylvania, Vereinigte Staaten, 18519
- Rekrutierung
- Geisinger Cancer Center Dickson City
-
Hauptermittler:
- Sorab Gupta
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-204-6081
- E-Mail: cancerresearch@geisinger.edu
-
Erie, Pennsylvania, Vereinigte Staaten, 16505
- Rekrutierung
- UPMC Hillman Cancer Center Erie
-
Hauptermittler:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-Mail: ClinicalResearchServices@upmc.edu
-
Erie, Pennsylvania, Vereinigte Staaten, 16544
- Rekrutierung
- Saint Vincent Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 814-452-5000
-
Hauptermittler:
- Alexander Helfand
-
Greensburg, Pennsylvania, Vereinigte Staaten, 15601
- Rekrutierung
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 724-838-1900
-
Hauptermittler:
- Leonard J. Appleman
-
Harrisburg, Pennsylvania, Vereinigte Staaten, 17109
- Rekrutierung
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-724-6765
- E-Mail: klitchfield@PINNACLEHEALTH.org
-
Hauptermittler:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Rekrutierung
- Penn State Milton S Hershey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-3779
- E-Mail: CTO@hmc.psu.edu
-
Hauptermittler:
- Monika Joshi
-
Indiana, Pennsylvania, Vereinigte Staaten, 15701
- Rekrutierung
- IRMC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-Mail: haneydl@upmc.edu
-
Hauptermittler:
- Leonard J. Appleman
-
Jefferson Hills, Pennsylvania, Vereinigte Staaten, 15025
- Rekrutierung
- Jefferson Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-359-3043
- E-Mail: ddefazio@wpahs.org
-
Hauptermittler:
- Alexander Helfand
-
Lewisburg, Pennsylvania, Vereinigte Staaten, 17837
- Rekrutierung
- Geisinger Medical Oncology-Lewisburg
-
Hauptermittler:
- Sorab Gupta
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-523-9200
- E-Mail: cancerresearch@geisinger.edu
-
Mechanicsburg, Pennsylvania, Vereinigte Staaten, 17050
- Rekrutierung
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-Mail: haneydl@upmc.edu
-
Hauptermittler:
- Leonard J. Appleman
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Rekrutierung
- Forbes Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-858-7746
-
Hauptermittler:
- Alexander Helfand
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Rekrutierung
- UPMC Hillman Cancer Center - Monroeville
-
Hauptermittler:
- Leonard J. Appleman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-Mail: ClinicalResearchServices@upmc.edu
-
Natrona Heights, Pennsylvania, Vereinigte Staaten, 15065
- Rekrutierung
- Allegheny Valley Hospital
-
Kontakt:
- Site Public Contact
- E-Mail: Dawnmarie.DeFazio@ahn.org
-
Hauptermittler:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Rekrutierung
- West Penn Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-578-5000
-
Hauptermittler:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15215
- Rekrutierung
- UPMC-Saint Margaret
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-784-4900
-
Hauptermittler:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15237
- Rekrutierung
- UPMC-Passavant Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-367-6454
-
Hauptermittler:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Rekrutierung
- Allegheny General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-284-2000
-
Hauptermittler:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Hauptermittler:
- Leonard J. Appleman
-
Seneca, Pennsylvania, Vereinigte Staaten, 16346
- Rekrutierung
- UPMC Cancer Center at UPMC Northwest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 814-676-7900
-
Hauptermittler:
- Leonard J. Appleman
-
Uniontown, Pennsylvania, Vereinigte Staaten, 15401
- Rekrutierung
- UPMC Cancer Center-Uniontown
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Leonard J. Appleman
-
Washington, Pennsylvania, Vereinigte Staaten, 15301
- Rekrutierung
- UPMC Cancer Center-Washington
-
Kontakt:
- Site Public Contact
- E-Mail: ecog.rss@jimmy.harvard.edu
-
Hauptermittler:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Rekrutierung
- Reading Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-988-9323
-
Hauptermittler:
- Terrence P. Cescon
-
Wexford, Pennsylvania, Vereinigte Staaten, 15090
- Rekrutierung
- Wexford Health and Wellness Pavilion
-
Kontakt:
- Site Public Contact
- E-Mail: Dawnmarie.DeFazio@ahn.org
-
Hauptermittler:
- Alexander Helfand
-
Wilkes-Barre, Pennsylvania, Vereinigte Staaten, 18711
- Rekrutierung
- Geisinger Wyoming Valley/Henry Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-Mail: HemonCCTrials@geisinger.edu
-
Hauptermittler:
- Sorab Gupta
-
-
South Dakota
-
Aberdeen, South Dakota, Vereinigte Staaten, 57401
- Rekrutierung
- Avera Cancer Institute-Aberdeen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-622-8700
- E-Mail: oncregulatory@avera.org
-
Hauptermittler:
- Ryan A. Vaca
-
Mitchell, South Dakota, Vereinigte Staaten, 57301
- Rekrutierung
- Avera Cancer Institute - Mitchell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3096
- E-Mail: OncRegulatory@avera.org
-
Hauptermittler:
- Ryan A. Vaca
-
Pierre, South Dakota, Vereinigte Staaten, 57501
- Rekrutierung
- Avera Cancer Institute at Pierre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-Mail: OncRegulatory@avera.org
-
Hauptermittler:
- Ryan A. Vaca
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Rekrutierung
- Avera Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-Mail: OncRegulatory@avera.org
-
Hauptermittler:
- Ryan A. Vaca
-
Yankton, South Dakota, Vereinigte Staaten, 57078
- Rekrutierung
- Avera Cancer Institute at Yankton
-
Hauptermittler:
- Ryan A. Vaca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-655-1800
- E-Mail: OncRegulatory@avera.org
-
-
Texas
-
Baytown, Texas, Vereinigte Staaten, 77521
- Rekrutierung
- Houston Methodist San Jacinto Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Patrick E. Prath
-
Cypress, Texas, Vereinigte Staaten, 77429
- Rekrutierung
- Houston Methodist Cypress Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 346-356-1413
- E-Mail: irb@houstonmethodist.org
-
Hauptermittler:
- Patrick E. Prath
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Dallas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Suzanne M. Cole
-
Dallas, Texas, Vereinigte Staaten, 75235
- Rekrutierung
- Parkland Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-590-5582
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Suzanne M. Cole
-
Dallas, Texas, Vereinigte Staaten, 75237
- Rekrutierung
- UT Southwestern Simmons Cancer Center - RedBird
-
Hauptermittler:
- Suzanne M. Cole
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Hauptermittler:
- Suzanne M. Cole
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Houston Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-790-2700
-
Hauptermittler:
- Patrick E. Prath
-
Houston, Texas, Vereinigte Staaten, 77070
- Rekrutierung
- Methodist Willowbrook Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Patrick E. Prath
-
Houston, Texas, Vereinigte Staaten, 77094
- Rekrutierung
- Houston Methodist West Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 832-522-2873
-
Hauptermittler:
- Patrick E. Prath
-
Nassau Bay, Texas, Vereinigte Staaten, 77058
- Rekrutierung
- Houston Methodist Saint John Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Patrick E. Prath
-
Richardson, Texas, Vereinigte Staaten, 75080
- Rekrutierung
- UT Southwestern Clinical Center at Richardson/Plano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-669-7044
- E-Mail: Suzanne.cole@utsouthwestern.edu
-
Hauptermittler:
- Suzanne M. Cole
-
Sugar Land, Texas, Vereinigte Staaten, 77479
- Rekrutierung
- Houston Methodist Sugar Land Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 281-242-2873
-
Hauptermittler:
- Patrick E. Prath
-
The Woodlands, Texas, Vereinigte Staaten, 77385
- Rekrutierung
- Houston Methodist The Woodlands Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-790-2700
- E-Mail: hmthewoodlands@houstonmethodist.org
-
Hauptermittler:
- Patrick E. Prath
-
-
Vermont
-
Berlin Corners, Vermont, Vereinigte Staaten, 05602
- Rekrutierung
- Central Vermont Medical Center/National Life Cancer Treatment
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-225-5400
-
Hauptermittler:
- Rahul Anil
-
Burlington, Vermont, Vereinigte Staaten, 05401
- Rekrutierung
- University of Vermont Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-4101
- E-Mail: rpo@uvm.edu
-
Hauptermittler:
- Rahul Anil
-
Burlington, Vermont, Vereinigte Staaten, 05405
- Rekrutierung
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-Mail: rpo@uvm.edu
-
Hauptermittler:
- Rahul Anil
-
Saint Johnsbury, Vermont, Vereinigte Staaten, 05819
- Rekrutierung
- Dartmouth Cancer Center - North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@hitchcock.org
-
Hauptermittler:
- Jacob B. Reibel
-
-
Virginia
-
Fredericksburg, Virginia, Vereinigte Staaten, 22408
- Rekrutierung
- Hematology Oncology Associates of Fredericksburg Inc
-
Kontakt:
- Site Public Contact
- Telefonnummer: 540-371-0079
- E-Mail: cvaughn@hoafredericksburg.com
-
Hauptermittler:
- Asit K. Paul
-
Richmond, Virginia, Vereinigte Staaten, 23229
- Rekrutierung
- Virginia Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-287-3000
- E-Mail: smoore@vacancer.com
-
Hauptermittler:
- Asit K. Paul
-
Richmond, Virginia, Vereinigte Staaten, 23235
- Rekrutierung
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-Mail: ctoclinops@vcu.edu
-
Hauptermittler:
- Asit K. Paul
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- VCU Massey Comprehensive Cancer Center
-
Hauptermittler:
- Asit K. Paul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-Mail: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Vereinigte Staaten, 98004
- Rekrutierung
- FHCC Overlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 425-454-2148
-
Hauptermittler:
- Mikhail G. Perlov
-
Kirkland, Washington, Vereinigte Staaten, 98034
- Rekrutierung
- FHCC at EvergreenHealth
-
Hauptermittler:
- Prakash Varadarajan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 425-899-6000
-
Seattle, Washington, Vereinigte Staaten, 98195
- Rekrutierung
- University of Washington Medical Center - Montlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hauptermittler:
- Petros Grivas
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Fred Hutchinson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hauptermittler:
- Petros Grivas
-
Seattle, Washington, Vereinigte Staaten, 98133
- Rekrutierung
- FHCC at Northwest Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-606-5800
-
Hauptermittler:
- Nellowe Candelario
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Rekrutierung
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hauptermittler:
- Kok Hoe Chan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-Mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Joyce Philip
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Rekrutierung
- Duluth Clinic Ashland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Rekrutierung
- Gundersen Lutheran Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-Mail: cancerctr@gundersenhealth.org
-
Hauptermittler:
- Kurt Oettel
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Rekrutierung
- Cancer Center of Western Wisconsin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patient must be ≥ 18 years of age
-
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer
-
Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded
-
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization
-
Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy
-
Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy
- NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
- NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
-
Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose
-
For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion
-
Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician
-
Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan
-
Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases
-
Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities
-
Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion
-
NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.
-
Examples of non-clinically significant laboratory abnormalities include, but are not limited to:
- Lymphopenia or monopenia
- Lymphocytosis or monocytosis
- Increase in amylase or lipase with no clinical correlation
- Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
-
NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization
-
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment
-
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)
-
Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)
-
Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)
-
Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)
-
Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)
-
Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm
- NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization
-
Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible
-
Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
-
Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.
- NOTE: Sites cannot translate the associated HRQOL forms
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm I (TPC chemotherapy)
Patients receive TPC with carboplatin or cisplatin IV on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and CT or MRI throughout the study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Given IV
Andere Namen:
|
|
Experimental: Arm II (pembrolizumab, sacituzumab govitecan-hziy)
Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study. |
Undergo blood sample collection
Andere Namen:
Undergo CT
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall survival (OS)
Zeitfenster: From randomization to death due to any cause, assessed up to 5 years
|
OS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The hazard ratio (HR) will be estimated, and a 95% confidence interval (CI) will be reported. |
From randomization to death due to any cause, assessed up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS)
Zeitfenster: From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
PFS will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PFS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
|
Overall response rate (ORR)
Zeitfenster: Up to 5 years
|
ORR will be assessed among patients who received at least one dose of protocol therapy using RECIST v 1.1 criteria. ORR will be defined as the number of patients with complete response (CR) and partial response (PR) divided by the number of treated patients. ORR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Clinical benefit rate (CBR)
Zeitfenster: Up to 5 years
|
CBR will be defined as CR, PR, or stable disease per RECIST v 1.1. CBR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Duration of response (DOR)
Zeitfenster: From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
DOR will be assessed by RECIST v1.1. DOR will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
|
Incidence of adverse events (AEs)
Zeitfenster: Up to 30 days after last dose of study drug
|
AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients with toxicities will be tabulated. The 90% CI for the true probability of observing toxicity of ≥ grade 4 on a given arm will be no wider than 12.3 %. The probability of observing ≥ 1 toxicity on a given arm with a true rate of 1% is 85.5%. |
Up to 30 days after last dose of study drug
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score
Zeitfenster: At baseline and at 3, 6 and 12 months
|
Change in patient reported FBISI-18 score will be compared between arms using a two-sample t-test. Assessment time will be considered as a continuous variable if there is a linear trend in quality of life (QOL) assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. A t-test will be performed to explore change of FBISI-18 summary score. |
At baseline and at 3, 6 and 12 months
|
|
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) summary score
Zeitfenster: At baseline and at 3, 6 and 12 months
|
Change in patient reported FACIT-F score will be compared between arms using a two-sample t-test. Mixed effect models will be constructed to estimate the time profile of FACIT-F in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in QOL assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. |
At baseline and at 3, 6 and 12 months
|
|
Change in quality-adjusted survival (assessed by the European Quality of Life Five Dimension Five Level scale [EQ-5D-5L]).
Zeitfenster: At baseline and at 3, 6 and 12 months
|
Change in patient reported EQ-5D-5L will be compared between the arms using a two-sample t-test. Quality-adjusted survival (assessed by the EQ-5D-5L), will be analyzed with quality-adjusted time without symptoms or toxicity. |
At baseline and at 3, 6 and 12 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Monika Joshi, ECOG-ACRIN Cancer Research Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Karzinom
- Karzinom, Übergangszelle
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Koordinationskomplexe
- Taxoid
- Cyclodececane
- Diterpene
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Elemente
- Metalle
- Gesundheitsökonomie und Organisationen
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Metalle, schwer
- Platinverbindungen
- Übergangselemente
- Wirtschaft
- Docetaxel
- Gemcitabin
- Carboplatin
- Paclitaxel
- Cisplatin
- 1,2-Diaminocyclohexanplatin-II-Citrat
- Handhabung von Proben
- Pembrolizumab
- Magnetresonanzspektroskopie
- Platin
- Sacituzumab Govitecan
- Steuern
Andere Studien-ID-Nummern
- NCI-2024-06208
- U10CA180820 (US NIH Stipendium/Vertrag)
- NCI-2024-06208 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- EA8231 (Andere Kennung: CTEP)
- EA8231 (Andere Kennung: ECOG-ACRIN Cancer Research Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .